S 337395
Alternative Names: S-337395Latest Information Update: 26 Jul 2024
At a glance
- Originator Shionogi; Ube Industries
- Developer Shionogi
- Class Antivirals; Small molecules
- Mechanism of Action RNA replicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Respiratory syncytial virus infections
Most Recent Events
- 19 Jun 2024 Shionogi completes a phase I trial in Respiratory syncytial virus infections (In volunteers) in USA (PO) (NCT06270511)
- 06 Mar 2024 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in USA (PO) (NCT06270511)
- 11 May 2023 Phase-I clinical trials in Respiratory syncytial virus infections (In volunteers) in Japan (PO), prior to May 2023 (jRCT2031230033)